Santhera Pharmaceuticals Holding AG Capital Reinvestment Ratio
Santhera Pharmaceuticals Holding AG capital reinvestment ratio. Santhera Pharmaceuticals Holding AG (SANN) has a Capital Reinvestment Ratio of 0.00x as of December 2023, meaning it reinvests 0% of its operating cash flow (CHF62.63 Million) in capital expenditures (CHF90.00K). Check SANN cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Santhera Pharmaceuticals Holding AG (2019–2023)
Capital reinvestment ratio of Santhera Pharmaceuticals Holding AG from 2019 to 2023. This chart tracks Santhera Pharmaceuticals Holding AG's Capital Reinvestment Ratio across 2 annual periods. Also explore net asset momentum of Santhera Pharmaceuticals Holding AG to track the company's year-over-year net asset growth rate.
Santhera Pharmaceuticals Holding AG Capital Reinvestment Ratio by Year (2019–2023)
Santhera Pharmaceuticals Holding AG capital reinvestment ratio by year from 2019 to 2023. For the full cash flow conversion analysis, see Santhera Pharmaceuticals Holding AG cash conversion from operations.
| Year | Reinvestment Ratio | Operating CF (CHF) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 0.50x | CHF47.27 Million | CHF23.74 Million | ▲ +469.2% |
| 2019 | 0.09x | CHF2.60 Million | CHF229.00K | — |